Characteristics | Statistics, n (%) |
N | 14 |
Age at infusion (years) | |
Mean (SD) | 66.9 (8.1) |
Median (range) | 66 (51–78) |
Gender | |
Male | 12 (85) |
Female | 2 (14) |
No. of previous therapies | |
Mean (SD) | 5.3 (2.8) |
Median (range) | 5 (1–11) |
P53 or 17p deletion | |
No | 8 (57) |
Yes | 6 (43) |
IGHV mutation | |
No | 9 (64) |
Yes | 4 (29) |
Unknown | 1 (7) |
Lymphocyte-depleting chemotherapy | |
Bendamustine | 6 (43) |
Fludarabine/cyclophosphamide | 3 (21) |
Pentostatin/cyclophosphamide | 5 (36) |
Lymphocytes in bone marrow at enrollment (%)* | |
Mean (SD) | 79.5 (17.9) |
Median (range) | 87.5 (40–95) |
Rai stage | |
1 | 5 (36) |
4 | 9 (64) |
Binet stage | |
A | 1 (7) |
B | 4 (29) |
C | 9 (64) |
*Data not available for four subjects.